MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyaf167

Медицинская библиотека · The oncologist · 2025

Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.

Odagiri Kunihiro, Mimura Yoshihisa, Naiki Taku, Tasaki Yoshihiko, Sugiyama Yosuke, Naiki-Ito Aya, Etani Toshiki, Nagai Takashi, Morikawa Toshiharu, Shimizu Nobuhiko, Aoki Maria, Gonda Masakazu, Yasui Takahiro, Furukawa-Hibi Yoko

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Cancer cachexia reduces chemotherapy efficacy in patients with metastatic urothelial carcinoma (mUC). Anamorelin improves cancer cachexia by increasing serum insulin-like growth factor 1 (IGF-1). The aim of this study was to evaluate the efficacy and safety of anamorelin in patients with mUC.

METHODS

A total of 38 patients with mUC who received platinum-based chemotherapy were enrolled in an interventional prospective study. Patients were randomized to anamorelin (Ana; n = 20) or control (n = 18) groups. The primary endpoint was the change in prealbumin. Secondary endpoints were changes in albumin, IGF-1, body weight, skeletal muscle mass index (SMI), interleukin-6 (IL-6) and median overall survival (mOS).

RESULTS

Changes in prealbumin, albumin, body weight, and SMI were similar between groups. Compared to control, serum IGF-1 levels in the anamorelin-treated group were higher after 1 week (P < .05). Changes in IGF-1 and SMI positively correlated in the anamorelin group (R = 0.61, P < .05). When the anamorelin group was divided into 2 groups by the median serum IGF-1 level after 1 week (Ana-IGF-1 high and Ana-IGF-1 low groups), the SMI in the latter group showed a decreased tendency (P = .14). The Ana-IGF-1 low group showed significantly higher IL-6 levels (P < .05) at baseline and significantly shorter mOS compared to the Ana-IGF-1 high group (P < .05). Treatment-related adverse events were comparable between the 2 groups (any grade: 100% vs 100%; grade ≥3: 88.9% vs 90.0%).

CONCLUSIONS

Anamorelin was well tolerated in patients with mUC. A higher serum IGF-1 level might be associated with anamorelin efficacy; however, a larger study is needed to confirm this.

Для цитирования: Odagiri Kunihiro, Mimura Yoshihisa, Naiki Taku, Tasaki Yoshihiko, Sugiyama Yosuke, Naiki-Ito Aya, Etani Toshiki, Nagai Takashi, Morikawa Toshiharu, Shimizu Nobuhiko, Aoki Maria, Gonda Masakazu, Yasui Takahiro, Furukawa-Hibi Yoko. Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.. The oncologist. 2025. DOI: 10.1093/oncolo/oyaf167.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.